tamibarotene has been researched along with bms 214662 in 1 studies
| Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (bms 214662) | Trials (bms 214662) | Recent Studies (post-2010) (bms 214662) |
|---|---|---|---|---|---|
| 198 | 10 | 105 | 49 | 8 | 9 |
| Protein | Taxonomy | tamibarotene (IC50) | bms 214662 (IC50) |
|---|---|---|---|
| GTPase HRas | Homo sapiens (human) | 0.0013 | |
| GTPase KRas | Homo sapiens (human) | 0.7723 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 0.3617 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.0021 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
1 review(s) available for tamibarotene and bms 214662
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |